Civamide for The Treatment of Herpes Simplex

Our long-term objective is the approval of a new drug application (NDA) for civamide as a topical therpes simplex virus (HSV) infections. In the United States, genital HSV affects more than 25 millioHSV effects up to 100 million individuals. The enormous number of affected individuals makes this ancommercial opportunity. In previous preclinical studies using the guinea pig model of HSV-type II inreduced the severity of both primary and recurrent herpes simplex infections. Most importantly, civaprimary infection appeared to reduce the severity of subsequent recurrences. This phase I proposal wfurther define the mechanism of action of civamide in this disease prior to clinical studies in phastechniques will be used to determine whether application of civamide is interfering with latency. Invanilloid receptor antagonist, we will determine whether binding of this receptor by civamide is necNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)